Outlook Therapeutics® to Participate in the Cantor Fitzgerald Medical & Aesthetic Dermatology, Ophthalmology & Medtech Conference
Retrieved on:
Thursday, December 1, 2022
In addition to the panel presentation, management will be available to participate in in-person one-on-one meetings with qualified members of the investor community who are registered to attend the conference.
Key Points:
- In addition to the panel presentation, management will be available to participate in in-person one-on-one meetings with qualified members of the investor community who are registered to attend the conference.
- The panel discussion is open to those who are registered to attend the event.
- The FDA accepted Outlook Therapeutics BLA submission for ONS-5010 to treat wet AMD with a PDUFA goal date of August 29, 2023.
- The submission is supported by Outlook Therapeutics wet AMD clinical program, which consists of three clinical trials: NORSE ONE, NORSE TWO, and NORSE THREE.